866-997-4948(US-Canada Toll Free)

Glial Cell Line Derived Neurotrophic Factor (Astrocyte Derived Trophic Factor or GDNF) - Pipeline Review, H2 2016

Published By :

Global Markets Direct

Published Date : Oct 2016

Category :

Pharmaceutical

No. of Pages : 48 Pages

Glial Cell Line Derived Neurotrophic Factor (Astrocyte Derived Trophic Factor or GDNF) - Pipeline Review, H2 2016

Summary

Global Markets Directs, Glial Cell Line Derived Neurotrophic Factor (Astrocyte Derived Trophic Factor or GDNF) - Pipeline Review, H2 2016, provides in depth analysis on Glial Cell Line Derived Neurotrophic Factor (Astrocyte Derived Trophic Factor or GDNF) targeted pipeline therapeutics.

The report provides comprehensive information on the Glial Cell Line Derived Neurotrophic Factor (Astrocyte Derived Trophic Factor or GDNF) , targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Glial Cell Line Derived Neurotrophic Factor (Astrocyte Derived Trophic Factor or GDNF) targeted therapeutics development and features dormant and discontinued projects.

Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note:
*Certain sections in the report may be removed or altered based on the availability and relevance of data.
*Updated report will be delivered in 48 hours of order confirmation.

Scope

- The report provides a snapshot of the global therapeutic landscape for Glial Cell Line Derived Neurotrophic Factor (Astrocyte Derived Trophic Factor or GDNF)
- The report reviews Glial Cell Line Derived Neurotrophic Factor (Astrocyte Derived Trophic Factor or GDNF) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Glial Cell Line Derived Neurotrophic Factor (Astrocyte Derived Trophic Factor or GDNF) targeted therapeutics and enlists all their major and minor projects
- The report assesses Glial Cell Line Derived Neurotrophic Factor (Astrocyte Derived Trophic Factor or GDNF) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Glial Cell Line Derived Neurotrophic Factor (Astrocyte Derived Trophic Factor or GDNF) targeted therapeutics

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Glial Cell Line Derived Neurotrophic Factor (Astrocyte Derived Trophic Factor or GDNF)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and its most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Glial Cell Line Derived Neurotrophic Factor (Astrocyte Derived Trophic Factor or GDNF) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Glial Cell Line Derived Neurotrophic Factor (Astrocyte Derived Trophic Factor or GDNF) Overview 6
Therapeutics Development 7
Glial Cell Line Derived Neurotrophic Factor (Astrocyte Derived Trophic Factor or GDNF) - Products under Development by Stage of Development 7
Glial Cell Line Derived Neurotrophic Factor (Astrocyte Derived Trophic Factor or GDNF) - Products under Development by Therapy Area 8
Glial Cell Line Derived Neurotrophic Factor (Astrocyte Derived Trophic Factor or GDNF) - Products under Development by Indication 9
Glial Cell Line Derived Neurotrophic Factor (Astrocyte Derived Trophic Factor or GDNF) - Pipeline Products Glance 10
Late Stage Products 10
Early Stage Products 11
Glial Cell Line Derived Neurotrophic Factor (Astrocyte Derived Trophic Factor or GDNF) - Products under Development by Companies 12
Glial Cell Line Derived Neurotrophic Factor (Astrocyte Derived Trophic Factor or GDNF) - Products under Development by Universities/Institutes 14
Glial Cell Line Derived Neurotrophic Factor (Astrocyte Derived Trophic Factor or GDNF) - Therapeutics Assessment 16
Assessment by Monotherapy/Combination Products 16
Assessment by Mechanism of Action 17
Assessment by Route of Administration 19
Assessment by Molecule Type 21
Glial Cell Line Derived Neurotrophic Factor (Astrocyte Derived Trophic Factor or GDNF) - Companies Involved in Therapeutics Development 23
NsGene A/S 23
UniQure N.V. 24
Glial Cell Line Derived Neurotrophic Factor (Astrocyte Derived Trophic Factor or GDNF) - Drug Profiles 25
AMT-140 - Drug Profile 25
Product Description 25
Mechanism Of Action 25
R&D Progress 25
Drugs for Neurodegenerative Diseases - Drug Profile 27
Product Description 27
Mechanism Of Action 27
R&D Progress 27
LAUR-301 - Drug Profile 28
Product Description 28
Mechanism Of Action 28
R&D Progress 28
NsG-0301 - Drug Profile 29
Product Description 29
Mechanism Of Action 29
R&D Progress 29
Recombinant Protein to Activate GDNF for Brain Ischemia - Drug Profile 30
Product Description 30
Mechanism Of Action 30
R&D Progress 30
smilagenin - Drug Profile 31
Product Description 31
Mechanism Of Action 31
R&D Progress 31
Stem Cell Therapy to Activate GDNF for Amyotrophic Lateral Sclerosis - Drug Profile 34
Product Description 34
Mechanism Of Action 34
R&D Progress 34
Glial Cell Line Derived Neurotrophic Factor (Astrocyte Derived Trophic Factor or GDNF) - Dormant Projects 35
Glial Cell Line Derived Neurotrophic Factor (Astrocyte Derived Trophic Factor or GDNF) - Featured News & Press Releases 36
Nov 28, 2013: Clinical trial launched to treat Sanfilippo B syndrome using gene therapy 36
Mar 26, 2013: Phytopharm Provides Strategic Review Update On On-going Phase II Clinical Trial Of Cogane 36
Feb 18, 2013: Phytopharm Announces Results From Parkinsons Disease Clinical Trial Of Cogane 37
Dec 18, 2012: Phytopharm Provides Update On Clinical Development Of Cogane In Amyotrophic Lateral Sclerosis 38
Apr 18, 2012: Phytopharm Completes Patient Recruitment In CONFIDENT-PD Phase II Cogane Study To Treat Parkinsons Disease 39
Apr 18, 2012: Phytopharm's Confirmatory Data Supports Effectiveness Of Phytopharm's Cogane In Amyotrophic Lateral Sclerosis 40
Jan 16, 2012: Phytopharm's Cogane Demonstrates Positive Results In Amyotrophic Lateral Sclerosis Study 41
Sep 29, 2011: European Commission Grants Orphan Drug Status For Phytopharm's Cogane For Treatment Of Amyotrophic Lateral Sclerosis 42
Jul 28, 2011: Phytopharm's Cogane Receives FDA Orphan Drug Status 42
Nov 17, 2010: Phytopharm Initiates Phase II Study Of Cogane In Patients With Parkinson's Disease 43
Jun 14, 2010: Phytopharm Receives FDA Approval To Begin Phase II Clinical Trial Of Cogane 43
Apr 20, 2009: Phytopharm Announces The Commencement Of Clinical Study of Cogane In Patients With Parkinsons Disease 44
Jan 21, 2008: Phytopharm Announces $1.16 million Funding For Cogane 45
Jun 05, 2007: Phytopharm plc Presents Cogane Data At 11th International Congress Of Parkinsons Disease And Movement Disorders 45
Nov 30, 2005: Phytopharm Announes That The Preliminary Trial Results Are Expected In December 2005 46
Appendix 47
Methodology 47
Coverage 47
Secondary Research 47
Primary Research 47
Expert Panel Validation 47
Contact Us 47
Disclaimer 48

List of Tables
Number of Products under Development for, H2 2016 7
Number of Products under Development by Therapy Area, H2 2016 8
Number of Products under Development by Indication, H2 2016 9
Comparative Analysis by Late Stage Development, H2 2016 10
Comparative Analysis by Early Stage Products, H2 2016 11
Number of Products under Development by Companies, H2 2016 12
Products under Development by Companies, H2 2016 13
Number of Products under Investigation by Universities/Institutes, H2 2016 14
Products under Investigation by Universities/Institutes, H2 2016 15
Assessment by Monotherapy/Combination Products, H2 2016 16
Number of Products by Stage and Mechanism of Action, H2 2016 18
Number of Products by Stage and Route of Administration, H2 2016 20
Number of Products by Stage and Molecule Type, H2 2016 22
Pipeline by NsGene A/S, H2 2016 23
Pipeline by UniQure N.V., H2 2016 24
Dormant Projects, H2 2016 35

List of Figures
Number of Products under Development for, H2 2016 7
Number of Products under Development by Indication, H2 2016 9
Comparative Analysis by Early Stage Products, H2 2016 11
Assessment by Monotherapy/Combination Products, H2 2016 16
Number of Products by Mechanism of Actions, H2 2016 17
Number of Products by Stage and Mechanism of Actions, H2 2016 17
Number of Products by Routes of Administration, H2 2016 19
Number of Products by Stage and Routes of Administration, H2 2016 19
Number of Products by Molecule Types, H2 2016 21
Number of Products by Stage and Molecule Type, H2 2016 21

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *